CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts conc ...

Core Insights - Rocket Pharmaceuticals (RCKT) has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy candidate RP-A601, aimed at treating PKP2-arrhythmogenic cardiomyopathy (ACM) [1][7] - The RMAT designation allows for enhanced interactions with the FDA, facilitating accelerated approval processes and early discussions on potential endpoints [2] Company Developments - Following the RMAT announcement, RCKT's shares increased by 16.8%, although the stock has decreased by 73.5% year-to-date, contrasting with a 0.7% decline in the industry [3] - The FDA's RMAT designation was based on positive safety and efficacy data from a phase I study, which indicated that RP-A601 is generally safe and well-tolerated [4][7] - RCKT is also developing another gene therapy candidate, RP-A701, for BAG3-associated dilated cardiomyopathy (BAG3-DCM), with the FDA recently approving its investigational new drug application [5][8] Recent Challenges - The company faced setbacks, including a voluntary pause in the pivotal phase II study of RP-A501 for Danon disease due to a patient death, leading to an FDA clinical hold [9] - Additionally, the FDA issued a complete response letter regarding the BLA for Kresladi, requesting more information on Chemistry Manufacturing and Controls, which has delayed the review process [10]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths, during the clinical trials [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about RP-A501's safety while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day. Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder. Since the May 27 announcement, a ...

PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses. Rocket Pharmaceuticals is headquartered in Cranbury, New J ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the announcement of a clinical hold by the FDA [3][4]. Group 1: Allegations and Events - The class period for the lawsuit is from February 27, 2025, to May 26, 2025 [3]. - Allegations include that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events (SAEs) [3]. - The company amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, leading to inflated stock prices [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a SAE, which ultimately resulted in death [3]. - Following the announcement, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 11, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc., and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the Phase 2 trial of RP-A501 for Danon disease, failing to disclose serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient died, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek to be appointed as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest and must be typical and adequate of the class [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its significant recoveries in securities fraud cases, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rocket Pharmaceuticals is facing a securities class action lawsuit alleging misleading safety disclosures related to its RP-A501 gene therapy program, which has resulted in significant stock price decline following a serious adverse event [1][3]. Company Overview - Rocket Pharmaceuticals, based in Cranbury, New Jersey, specializes in developing gene therapies for rare diseases [2]. Legal Allegations - The lawsuit claims that Rocket Pharmaceuticals did not inform investors about a significant protocol change involving a new immunomodulatory agent before a serious adverse event occurred, leading to a clinical hold by the FDA [3]. - Following the disclosure of a patient death during the trial, Rocket Pharmaceuticals' stock plummeted nearly 37%, dropping from $6.27 on May 23, 2025, to $2.33 on May 27, 2025 [3]. Investor Information - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may be eligible for recovery, with a lead plaintiff application deadline set for August 11, 2025 [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].